VIP and multiple sclerosis: In the last two decades, VIP and its receptors have emerged as potential pharmacological targets for various diseases, including asthma, brain stroke, chronic inflammation (Crohn’s disease, rheumatoid arthritis, septic shock, multiple sclerosis, etc.), neurodegenerative disorders, as well as cancers [17].